Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX)

NCT06114082 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06114082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06114082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX)
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2023
Completion date
July 1, 2026
Enrollment
128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer